Compare Adaptive Biotechnologies Corp (ADPT) vs Roblox Corp (RBLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Roblox Corp — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Roblox Corp trades at $54.59 (market cap $40.60B). The key difference: Roblox Corp is far larger — about 12.2× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | RBLX | |
|---|---|---|
Market Cap | $3.33B | $40.60B |
Sector | Health | Media |
52-Week High | $22.37 | $141.56 |
52-Week Low | $10.24 | $41.30 |
Enterprise Value | $3.19B | $39.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Roblox trades at $56.70, up 2.31% with strong technical momentum and bullish moving average signals. The company shows impressive revenue growth to $4.89 billion in 2025 and positive operating cash flow of $1.80 billion, though it remains unprofitable with a -20.69% net margin. Recent earnings beats and analyst consensus of $64.07 price target suggest upside potential, but multiple class action lawsuits filed in July 2026 create significant legal overhang.
While Roblox demonstrates strong user monetization and cash generation, profitability challenges and legal risks weigh on investor sentiment. The stock offers growth exposure but requires careful risk management given the negative earnings profile and ongoing litigation. Analyst optimism appears tempered by fundamental weaknesses and recent legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
